Nuformix (LSE:NFX) Interest Income : £0.00 Mil (TTM As of Sep. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Nuformix Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Nuformix's interest income for the six months ended in Sep. 2022 was £0.00 Mil. Its interest income for the trailing twelve months (TTM) ended in Sep. 2022 was £0.00 Mil.

Nuformix Interest Income Historical Data

The historical data trend for Nuformix's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuformix Interest Income Chart

Nuformix Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Interest Income

Get a 7-Day Free Trial

Nuformix Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23
Interest Income	Get a 7-Day Free Trial									-	-	-	-	-

Nuformix Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Sep. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

Nuformix (LSE:NFX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuformix PLC (LSE:NFX) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

1RT:Germany

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.nuformix.com

Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.